Schering-Plough's Integrilin improves artery blood flow in ER heart-attack patients

By Angela McDaniels

Seattle, Nov. 14 - Schering-Plough Corp. said that results from a phase 4 study show that the early initiation of Integrilin in emergency rooms prior to percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction yielded superior coronary artery blood flow.

"The longer a patient has poor blood flow to the heart, the higher the risk of cardiovascular damage," principal investigator C. Michael Gibson of Brigham and Women's Hospital said in a company news release.

"Since delays in restoring blood flow via angioplasty are frequent, this trial demonstrated that the strategy of early intervention in the emergency department with Integrilin improved blood flow prior to angioplasty."

Results from the 343-patient, multicenter study were presented during a symposium hosted by the Texas Heart Institute in Dallas on Saturday.

Kenilworth, N.J.-based Schering-Plough is a health care company that develops prescription, consumer and animal health products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.